Haemonetics (HAE) vs Heartflow (HTFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Haemonetics (HAE) has outperformed Heartflow (HTFL) over the past year, gaining 134.3% versus a gain of 33.2%. Haemonetics is the larger company by market cap ($5.44 billion vs $4.14 billion), about 1.3 times the size, while Heartflow is growing revenue faster (+39.9% vs -2.0%). Haemonetics converts more of its revenue into profit, with a net margin of 7.3% versus -66.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | HTFL |
|---|---|---|
| Share price | $119.47 | $47.63 |
| Market cap | $5.44B | $4.14B |
| 1-day change | +17.46% | -3.50% |
| YTD return | +49.06% | +63.40% |
| 1-year return | +134.35% | +33.19% |
| 5-year return | +70.89% | — |
| P/E ratio (TTM) | 57.71 | — |
| Forward P/E | 20.53 | — |
| EPS (TTM) | $2.07 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $176.03M |
| Revenue growth (YoY) | -1.97% | +39.92% |
| Net income (latest FY) | $97.31M | $-116.79M |
| Gross margin | 59.04% | 76.80% |
| Operating margin | 11.75% | -36.39% |
| Net margin | 7.29% | -66.35% |
| 52-week high | $121.00 | $54.32 |
| 52-week low | $48.17 | $20.13 |
| Distance from 52-week high | -1.26% | -12.32% |
| Analyst consensus | buy | none |
| Avg. price target upside | -6.67% | -3.42% |
| Average volume | 715.68K | 1.79M |
| Shares outstanding | 45.50M | 86.95M |
| Employees | 3,009 | 843 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed HTFL by 101.2 percentage points over the past year.
- Haemonetics is more profitable, keeping 7.3 cents of every revenue dollar as net income versus -66.3 cents for Heartflow.
- Heartflow grew revenue faster in its latest fiscal year (+39.92% vs -1.97%).
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Heartflow
HTFL stock →HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries.
Health Care · Medical/Dental Instruments · 843 employees
HAE vs HTFL FAQ
Which is bigger, Haemonetics or Heartflow?
Haemonetics (HAE) is larger, with a market capitalization of $5.44B compared with $4.14B for Heartflow (HTFL).
Which stock has performed better over the past year, HAE or HTFL?
HAE returned +134.35% over the past 12 months, compared with +33.19% for HTFL (price return, excluding dividends). Past performance does not predict future results.
Are Haemonetics and Heartflow in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.